Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...

Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care ...

Pfizer recalled Oxbryta and ended clinical trials over safety concerns, but sickle cell advocates are warning that stopping the drug abruptly could be dangerous.

Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.

Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...

Current sickle cell disease treatment options include: A cornerstone of SCD treatment since 1988, hydroxyurea works by increasing the production of hemoglobin F, which helps prevent the formation of ...

Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...

The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Agios Pharma (AGIO – Research Report) yesterday and set a ...

After Pfizer withdrew its sickle cell drug from the market, patients with the condition and their doctors were left ...

Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...

Agios Pharmaceuticals (AGIO) stock was downgraded at Leerink Partners on Pfizer's (PFE) recent decision to withdraw sickle ...